Literature DB >> 17555466

A re-evaluation of kava (Piper methysticum).

E Ernst1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17555466      PMCID： PMC2048557          DOI： 10.1111/j.1365-2125.2007.02932.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  21 in total

Review 1.  Potential for interaction of kava and St. John's wort with drugs.

Authors:  Yadhu N Singh
Journal:  J Ethnopharmacol       Date:  2005-08-22       Impact factor: 4.360

2.  [D,L-kavain in comparison with oxazepam in anxiety disorders. A double-blind study of clinical effectiveness].

Authors:  D Lindenberg; H Pitule-Schödel
Journal:  Fortschr Med       Date:  1990-01-20

3.  Liver function test abnormalities in users of aqueous kava extracts.

Authors:  Alan R Clough; Ross S Bailie; Bart Currie
Journal:  J Toxicol Clin Toxicol       Date:  2003

4.  Health effects of kava use in an eastern Arnhem Land Aboriginal community.

Authors:  A R Clough; S P Jacups; Z Wang; C B Burns; R S Bailie; S J Cairney; A Collie; T Guyula; S P McDonald; B J Currie
Journal:  Intern Med J       Date:  2003-08       Impact factor: 2.048

Review 5.  Pharmacokinetic and pharmacodynamic drug interactions with Kava (Piper methysticum Forst. f.).

Authors:  Jennifer Anke; Iqbal Ramzan
Journal:  J Ethnopharmacol       Date:  2004-08       Impact factor: 4.360

6.  Kava lactones and the kava-kava controversy.

Authors:  Peter A Whitton; Andrew Lau; Alicia Salisbury; Julie Whitehouse; Christine S Evans
Journal:  Phytochemistry       Date:  2003-10       Impact factor: 4.072

7.  Desmethoxyyangonin and dihydromethysticin are two major pharmacological kavalactones with marked activity on the induction of CYP3A23.

Authors:  Yuzhong Ma; Karuna Sachdeva; Jirong Liu; Michael Ford; Dongfang Yang; Ikhlas A Khan; Clinton O Chichester; Bingfang Yan
Journal:  Drug Metab Dispos       Date:  2004-07-28       Impact factor: 3.922

8.  Enhanced cognitive performance and cheerful mood by standardized extracts of Piper methysticum (Kava-kava).

Authors:  Richard Thompson; Willibald Ruch; Rüdiger U Hasenöhrl
Journal:  Hum Psychopharmacol       Date:  2004-06       Impact factor: 1.672

Review 9.  Toxicity of kava pyrones, drug safety and precautions--a case study.

Authors:  Johannes Schulze; Walter Raasch; Claus-Peter Siegers
Journal:  Phytomedicine       Date:  2003       Impact factor: 5.340

10.  Kava-Kava extract LI 150 is as effective as Opipramol and Buspirone in Generalised Anxiety Disorder--an 8-week randomized, double-blind multi-centre clinical trial in 129 out-patients.

Authors:  R J Boerner; H Sommer; W Berger; U Kuhn; U Schmidt; M Mannel
Journal:  Phytomedicine       Date:  2003       Impact factor: 5.340
View more
  7 in total

1.  Kava, the anxiolytic herb: back to basics to prevent liver injury?

Authors:  Rolf Teschke; Jerome Sarris; Xaver Glass; Johannes Schulze
Journal:  Br J Clin Pharmacol       Date:  2011-03       Impact factor: 4.335

2.  Kava hepatotoxicity in traditional and modern use: the presumed Pacific kava paradox hypothesis revisited.

Authors:  Rolf Teschke; Jerome Sarris; Isaac Schweitzer
Journal:  Br J Clin Pharmacol       Date:  2012-02       Impact factor: 4.335

Review 3.  Pharmacotherapy for generalized anxiety disorder in adult and pediatric patients: an evidence-based treatment review.

Authors:  Jeffrey R Strawn; Laura Geracioti; Neil Rajdev; Kelly Clemenza; Amir Levine
Journal:  Expert Opin Pharmacother       Date:  2018-07       Impact factor: 3.889

4.  Identification of methysticin as a potent and non-toxic NF-kappaB inhibitor from kava, potentially responsible for kava's chemopreventive activity.

Authors:  Ahmad Ali Shaik; David Lee Hermanson; Chengguo Xing
Journal:  Bioorg Med Chem Lett       Date:  2009-08-06       Impact factor: 2.823

5.  Candyflipping and Other Combinations: Identifying Drug-Drug Combinations from an Online Forum.

Authors:  Michael Chary; David Yi; Alex F Manini
Journal:  Front Psychiatry       Date:  2018-04-30       Impact factor: 4.157

6.  Crystal structure, Hirshfeld surface analysis and DFT calculations of (E)-3-[1-(2-hy-droxy-phenyl-anilino)ethyl-idene]-6-methyl-pyran-2,4-dione.

Authors:  Imane Faraj; Ali Oubella; Karim Chkirate; Khalil Al Mamari; Tuncer Hökelek; Joel T Mague; Lhoussaine El Ghayati; Nada Kheira Sebbar; El Mokhtar Essassi
Journal:  Acta Crystallogr E Crystallogr Commun       Date:  2022-07-29

7.  Kava for the treatment of generalised anxiety disorder (K-GAD): study protocol for a randomised controlled trial.

Authors:  Karen M Savage; Con K Stough; Gerard J Byrne; Andrew Scholey; Chad Bousman; Jenifer Murphy; Patricia Macdonald; Chao Suo; Matthew Hughes; Stuart Thomas; Rolf Teschke; Chengguo Xing; Jerome Sarris
Journal:  Trials       Date:  2015-11-02       Impact factor: 2.279
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.